Journal: British Journal of Clinical Pharmacology

Article Title: AKT in cancer: new molecular insights and advances in drug development

doi: 10.1111/bcp.13021

Figure Lengend Snippet: Ongoing clinical trials involving AKT inhibitors as registered on clinicaltrials.gov as of October 2015

Article Snippet: Ib Triple negative BC and gynaecological cancers with carboplatin and paclitaxel KRX‐0401 Aeterna Zentaris Perifosine Pan‐AKT (lipid‐based/PIP3 inhibitor) II Gliomas combined with temsirolimus PTX‐200 Prescient Therapeutics Triciribine PH domain (AKT) inhibitor I/II Advanced or metastatic HER2‐negative BC with paclitaxel, doxorubicin and cyclophosphamide AG1343 Roche Nelfinavir; Viracept HIV protease inhibitor, AKT I/II Multiple myeloma with lenalidomide + dexamethasone ‐‐‐ Multiple trials in multiple Ca types as radiosensitizing agent ONC‐201 Oncoceutics TRAIL pathway inducing compound/indirect AKT inhibitor I Solid tumours I/II Relapsed/refractory NHL I/II Relapsed/refractory AML and high‐risk MDS Archexin Rexahn AKT1 antisense oligonucleotide I/II Renal cell Ca with everolimus Open in a separate window AML, acute myeloid leukaemia; BC, breast cancer; Ca, cancer; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B‐cell lymphoma; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HIV, human immunodeficiency virus; HR, hormone receptor; MDS, myelodysplastic syndrome; mTOR, mammalian target of rapamycin; NHL, non‐Hodgkin's lymphoma; PH, pleckstrin homology; PIP3, phosphatidylinositol 3,4,5‐trisphosphate; PIK3CA, PIK3 catalytic subunit alpha; PTEN, phosphatase and tensin homologue deleted on chromosome 10; TRAIL, tumour necrosis factor‐related apoptosis‐inducing ligand.

Techniques: Clinical Proteomics, Protease Inhibitor